BUZZ-Pacific Biosciences falls on Q4 revenue miss

Reuters

Feb 14, 2025

** Shares of life sciences company Pacific Biosciences PACB.O fall 2% to $1.45 premarket

** It reported Q4 revenue of $39.2 million late on Thursday, a decrease of 33% from the prior year and missing estimates of $40.2 million, according to data compiled by LSEG

** The company forecast 2025 revenue to range between $155 million and $170 million, versus an estimate of $172.4 million

** The forecast includes factors such as the recent announcement to cap National Institutes of Health funding, it says

** "We're in the early innings of FY25 and uncertainties remain high, making the error bars wide this year. Debates likely center around the outlook and PACB's ability to return to growth, and after a year of misses/guide downs, execution will be key this year" - brokerage Stephens

** The stock fell 81.4% in 2024

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2511693161"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2511693161\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2511693161?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-14 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511693161","market":"us","top_or_hot":-1,"title":"BUZZ-Pacific Biosciences falls on Q4 revenue miss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Pacific Biosciences falls on Q4 revenue miss</title></head><body><p>** Shares of life sciences company Pacific Biosciences <span>PACB.O</span> fall 2% to $1.45 premarket</p><p>** It reported Q4 revenue of $39.2 million late on Thursday, a decrease of 33% from the prior year and missing estimates of $40.2 million, according to data compiled by LSEG</p><p>** The company forecast 2025 revenue to range between $155 million and $170 million, versus an estimate of $172.4 million </p><p>** The forecast includes factors such as the recent announcement to cap National Institutes of Health <span>funding</span>, it says</p><p>** \"We're in the early innings of FY25 and uncertainties remain high, making the error bars wide this year. Debates likely center around the outlook and PACB's ability to return to growth, and after a year of misses/guide downs, execution will be key this year\" - brokerage Stephens</p><p>** The stock fell 81.4% in 2024</p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Pacific Biosciences falls on Q4 revenue miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Pacific Biosciences falls on Q4 revenue miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-14 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Pacific Biosciences falls on Q4 revenue miss</title></head><body><p>** Shares of life sciences company Pacific Biosciences <span>PACB.O</span> fall 2% to $1.45 premarket</p><p>** It reported Q4 revenue of $39.2 million late on Thursday, a decrease of 33% from the prior year and missing estimates of $40.2 million, according to data compiled by LSEG</p><p>** The company forecast 2025 revenue to range between $155 million and $170 million, versus an estimate of $172.4 million </p><p>** The forecast includes factors such as the recent announcement to cap National Institutes of Health <span>funding</span>, it says</p><p>** \"We're in the early innings of FY25 and uncertainties remain high, making the error bars wide this year. Debates likely center around the outlook and PACB's ability to return to growth, and after a year of misses/guide downs, execution will be key this year\" - brokerage Stephens</p><p>** The stock fell 81.4% in 2024</p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PACB","symbol_name":"Pacific Biosciences of Californi","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nL4N3P513W:1","article_id":"2511693161","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511693161","pubTimestamp":1739541704,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Pacific Biosciences falls on Q4 revenue miss** Shares of life sciences company Pacific Biosciences PACB.O fall 2% to $1.45 premarket** It reported Q4 revenue of $39.2 million late on Thursday, a decrease of 33% from the prior year and missing estimates of $40.2 million, according to data compiled by LSEG** The company forecast 2025 revenue to range between $155 million and $170 million, versus an estimate of $172.4 million ** The forecast includes factors such as the recent announcement to cap National Institutes of Health funding, it says** \"We're in the early innings of FY25 and uncertainties remain high, making the error bars wide this year. Debates likely center around the outlook and PACB's ability to return to growth, and after a year of misses/guide downs, execution will be key this year\" - brokerage Stephens** The stock fell 81.4% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PACB":"Pacific Biosciences of Californi"},"translate_title":"BUZZ-Pacific Biosciences因第四季度收入未达预期而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PACB":0.9},"content_text":"BUZZ-Pacific Biosciences falls on Q4 revenue miss** Shares of life sciences company Pacific Biosciences PACB.O fall 2% to $1.45 premarket** It reported Q4 revenue of $39.2 million late on Thursday, a decrease of 33% from the prior year and missing estimates of $40.2 million, according to data compiled by LSEG** The company forecast 2025 revenue to range between $155 million and $170 million, versus an estimate of $172.4 million ** The forecast includes factors such as the recent announcement to cap National Institutes of Health funding, it says** \"We're in the early innings of FY25 and uncertainties remain high, making the error bars wide this year. Debates likely center around the outlook and PACB's ability to return to growth, and after a year of misses/guide downs, execution will be key this year\" - brokerage Stephens** The stock fell 81.4% in 2024 (Reporting by Sneha S K) ((Sneha.SK@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}